NCT06669403
OPT101 in Patients With Community Acquired Pneumonia (CAP) With Sepsis
At risk: Primary completion moved at least 10 months later.
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 4 versions: 4 with changes below. See every version on ClinicalTrials.gov ↗
Notable Primary and study completion dates pushed to Mar 2027 Show 5 more changesShow less
- Recruitment opened
- Eligibility criteria expanded, about 21 words
- Study sites: 1 to 2
- Start date changed from estimate of Dec 2025 to Mar 9, 2026
- Secondary endpoints: details revised at 2 of 5 entries
- Notable Start date: Jun 2025 to Dec 2025v3
- Notable Start date: Feb 2025 to Jun 2025
- Site contact updated
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Incidence of treatment-emergent adverse events (TEAEs)
Timeframe: 30 days
Incidence of serious adverse events (SAEs)
Timeframe: 30 days
Incidence of TEAEs leading to study drug discontinuation
Timeframe: 30 days
Incidence and characteristics of presumed infusion reactions
Timeframe: 30 days
Secondary (1)
To measure the serum pharmacokinetics of OPT101
Arms and interventions
0.9% Sodium Chloride Injection USPPlacebo comparator
Placebo will be 50mL normal saline (Sodium Chloride), USP sterile solution provided in a 50mL pre-packaged Intravenous (IV) bag.
OPT101Experimental
OPT101 (15-mer peptide) will be provided across 2 cohorts at 1.1 (cohort 1) and 2.8 mg/kg (cohort 2) doses . On the day of administration, the product will be diluted in saline to result in 50 mL for intravenous (IV) infusion over 120 minutes.
Drugs: OPT101
Other: Placebo
Sites
2 sites in 1 country